IX Draconis - a curious ER UMa-type dwarf nova

We report results of an extensive world-wide observing campaign devoted to a very active dwarf nova star - IX Draconis. We investigated photometric behaviour of the system to derive its basic outburst properties and understand peculiarities of IX Dra as well as other active cataclysmic variables, in particular dwarf novae of the ER Uma-type. In order to measure fundamental parameters of the system, we carried out analyses of the light curve, O-C diagram, and power spectra. During over two months of observations we detected two superoutbursts and several normal outbursts. The V magnitude of the star varied in the range 14.6 - 18.2 mag. Superoutbursts occur regularly with the supercycle length of 58.5+/-0.5 d. When analysing data over the past 20 years, we found that the supercycle length is increasing at a rate of P_dot = 1.8 * 10^{-3}. Normal outbursts appear to be irregular, with typical occurrence times in the range 3.1 - 4.1 d. We detected a double-peaked structure of superhumps during superoutburst, with the secondary maximum becoming dominant near the end of the superoutburst. The mean superhump period observed during superoutbursts equals 0.066982(36) d, which is constant over the last two decades of observations. Based on the power spectrum analysis, the evaluation of the orbital period was problematic. We found two possible values: the first one, 0.06641(3) d, which is in agreement with previous studies and our O-C analysis (0.06646(2) d), and the second one, 0.06482(3) d, which is less likely. The evolutionary status of the object depends dramatically on the choice between these two values. A spectroscopic determination of the orbital period is needed. We updated available information on ER UMa-type stars and present a new set of their basic statistics. Thereby, we provide evidence that this class of stars is not uniform.Comment: Accepted for publication in MNRAS; 15 pages, 15 figures, 6 tables; typo correcte

HT Cas - eclipsing dwarf nova during its superoutburst in 2010

We present results of a world-wide observing campaign of the eclipsing dwarf nova - HT Cas during its superoutburst in November 2010. Using collected data we were able to conduct analysis of the light curves and we calculated $O-C$ diagrams. The CCD photometric observations enabled us to derive the superhump period and with the timings of eclipses the orbital period was calculated. Based on superhump and orbital period estimations the period excess and mass ratio of the system were obtained

MN Draconis - peculiar, active dwarf nova in the period gap

Context: We present results of an extensive world-wide observing campaign of MN Draconis. Aims: MN Draconis is a poorly known active dwarf nova in the period gap and is one of the only two known cases of period gap SU UMa objects showing the negative superhumps. Photometric behaviour of MN Draconis poses a challenge for existing models of the superhump and superoutburst mechanisms. Therefore, thorough investigation of peculiar systems, such as MN Draconis, is crucial for our understanding of evolution of the close binary stars. Methods: To measure fundamental parameters of the system, we collected photometric data in October 2009, June-September 2013 and June-December 2015. Analysis of the light curves, $O-C$ diagrams and power spectra was carried out. Results: During our three observational seasons we detected four superoutburts and several normal outbursts. Based on the two consecutive superoutbursts detected in 2015, the supercycle length was derived P_sc = 74 +/- 0.5 days and it has been increasing with a rate of P_dot = 3.3 x 10^(-3) during last twelve years. Based on the positive and negative superhumps we calculated the period excess epsilon = 5.6% +/- 0.1%, the period deficit epsilon_ = 2.5% +/- 0.6%, and in result, the orbital period P_orb = 0.0994(1) days (143.126 +/- 0.144 min). We updated the basic light curve parameters of MN Draconis. Conclusions: MN Draconis is the first discovered SU UMa system in the period gap with increasing supercycle length.Comment: 14 pages, 20 figures, 8 tables, accepted for publication in Astronomy and Astrophysic

Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study

BACKGROUND Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the fastest growing HIV epidemics, compared to the rest of Europe. This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina. METHODS 13,310 individuals under follow-up were included in the analysis. Poisson regression investigated factors associated with the risk of death. FINDINGS During 82,212 person years of follow-up (PYFU) 1,147 individuals died (mortality rate 14.0 per 1,000 PYFU (95% confidence interval [CI] 13.1-14.8). Significant differences between regions were seen in the rate of all-cause, AIDS and non-AIDS related mortality (global p<0.0001 for all three endpoints). Compared to South Europe, after adjusting for baseline demographics, laboratory measurements and treatment, a higher rate of AIDS related mortality was observed in East Europe (IRR 2.90, 95%CI 1.97-4.28, p<.0001), and a higher rate of non-AIDS related mortality in North Europe (IRR 1.51, 95%CI 1.24-1.82, p<.0001). The differences observed in North Europe decreased over calendar-time, in 2009-2011, the higher rate of non-AIDS related mortality was no longer significantly different to South Europe (IRR 1.07, 95%CI 0.66-1.75, p = 0.77). However, in 2009-2011, there remained a higher rate of AIDS-related mortality (IRR 2.41, 95%CI 1.11-5.25, p = 0.02) in East Europe compared to South Europe in adjusted analysis. INTERPRETATIONS There are significant differences in the rate of all-cause mortality among HIV-positive individuals across different regions of Europe and Argentina. Individuals in Eastern Europe had an increased risk of mortality from AIDS related causes and individuals in North Europe had the highest rate of non-AIDS related mortality. These findings are important for understanding and reviewing HIV treatment strategies and policies across the European region

Corneal perforation requiring corneal grafting: a rare complication of gonococcal eye infection

International audienceWe present a case of severe gonococcal conjunctivitis associated with corneal perforation of the right eye in a 25 year-old homosexual man. Inpatient management and corneal grafting were required. We demonstrate that GC should be considered in the presence of purulent conjunctival discharge with a white patch on the cornea or reduced vision. Regardless of whether a patient has genital symptoms, they should be referred urgently to an ophthalmologist to ensure adequate treatment of this rare but sight threatening complication

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Objectives: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. Methods: The EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. Results: The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65–1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76–1.72 for RALvs. CONC). Conclusions: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.Peer reviewe

Influence of pH and ionic strength on the color parameters and antioxidant properties of an ethanolic red grape marc extract

The aim of present study was to investigate the influences of pH and several salts on the antioxidant activity and color of an ethanolic grape marc extract. Furthermore, the phenolic content of the extract was analyzed using HPLC and spectrophotometric methods while the total antioxidant activity was assessed by the reaction with ABTS radical. Gallic acid, procyanidins B1, B2, polydatin, catechin, epicatechin, hyperoside, ferulic, chlorogenic, and salicylic acids were among the main identified polyphenols. Different pH values had slight influence on the antioxidant activity, the highest value being determined for pH 3.7. The redness, chroma, and hue were significantly enhanced at pH 3.7 and 2.6. The chromaticity decreased at pH = 5.5 and pH = 7.4, so the extract should be used with care in products with such media. The presence of salts did not noticeably affect the antioxidant activity, except the higher concentrations of CaCl2, which decreased the antioxidant activity but enhanced the color intensity

SPG20 Protein Spartin Associates with Cardiolipin via Its Plant-Related Senescence Domain and Regulates Mitochondrial Ca2+ Homeostasis

Hereditary spastic paraplegias (HSPs) are a group of neurological disorders characterized clinically by spasticity of lower limbs and pathologically by degeneration of the corticospinal tract. Troyer syndrome is an autosomal recessive HSP caused by a frameshift mutation in the spartin (SPG20) gene. Previously, we established that this mutation results in a lack of expression of the truncated mutant spartin protein. Spartin is involved in many cellular processes and associates with several intracellular organelles, including mitochondria. Spartin contains a conserved plant-related senescence domain at its C-terminus. However, neither the function of this domain nor the roles of spartin in mitochondrial physiology are currently known. In this study, we determined that the plant-related senescence domain of spartin interacts with cardiolipin but not with two other major mitochondrial phospholipids, phosphatidylcholine and phosphatidylethanolamine. We also found that knockdown of spartin by small interfering RNA in a human neuroblastoma cell line resulted in depolarization of the mitochondrial membrane. In addition, depletion of spartin resulted in a significant decrease in both mitochondrial calcium uptake and mitochondrial membrane potential in cells treated with thapsigargin. Our results suggest that impairment of mitochondrial calcium uptake might contribute to the neurodegeneration of long corticospinal axons and the pathophysiology of Troyer syndrome

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment

Background: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. / Methods: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody–negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA–negative); or HCV treatment failures (HCV RNA–positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non–acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). / Results: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1–13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0–6.9) for CVD, 6.5 (95% CI 6.1–6.9) for NADM, and 3.1 (95% CI 2.8–3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14–0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36–1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02–2.13) or treatment failure (aIRR 1.80, 95% CI 1.22–2.66) had significantly raised rates of ESLD, compared to those who were cured. / Conclusions: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD